Dosage and administration
adults and children 2 years and over clean the affected area lightly apply to the affected area 1 to 3 times daily may be covered with a sterile bandage Children under 2 years, consult a doctor.
adults and children 2 years and over clean the affected area lightly apply to the affected area 1 to 3 times daily may be covered with a sterile bandage Children under 2 years, consult a doctor.
Lidocaine 2.00%
Benzalkonium Chloride 0.13%
Topical Analgesic/Anesthetic
First Aid Antiseptic
For temporary relief of pain or discomfort, for first degree burns or superficial second degree burns and to help prevent infection in: minor burns, cuts, scrapes.
burn in severe
increased redness or weeping or pain persist or clears up and occurs again within a few days
In case of accidental ingestion, get medical help or contact a Poison Control Center right away.
adults and children 2 years and over
allantoin, allium cepa (onion) bulb extract, aloe barbadensis leaf juice, benzyl alcohol, butylene glycol, calophyllum tacamahaca (tamanu) seed oil, camellia sinensis leaf extract, centella asiatica extract, citric acid, glycerin, melaleuca alternifolia (tea tree) leaf oil, methylisothiazolinone, phenoxyethanol, phytonadione, polysorbate 60, propylene glycol, sodium polyacrylate, water (aqua).
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 1052429 | benzalkonium chloride 0.13 % / lidocaine 2 % Topical Gel | PSN | 7 |
| 1052431 | scar zone burn gel 2 % / 0.13 % Topical Gel | PSN | 7 |
| 1052431 | benzalkonium chloride 0.0013 MG/MG / lidocaine 0.02 MG/MG Topical Gel [Scar Zone Burn Relief] | SBD | 7 |
| 1052429 | benzalkonium chloride 0.0013 MG/MG / lidocaine 0.02 MG/MG Topical Gel | SCD | 7 |
| 1052429 | benzalkonium chloride 0.13 % / lidocaine 2 % Topical Gel | SY | 7 |
| 1052431 | Scar Zone Burn Gel (lidocaine 2 % / benzalkonium chloride 0.13 % ) Topical Gel | SY | 7 |
| Class | Version | Type | Effective |
|---|---|---|---|
| LIDOCAINE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 16a2c1cd-ae95-d910-f03d-7e06b11dd243 | Product name | 5 | 20260202 |
| 653485de-0601-41e4-82db-7a60bb223e27 | Product name | 1 | 20251024 |
| 23fb3cda-2b50-f3d3-ebde-f542350bd77b | Product name | 4 | 20240828 |
| 081b54f0-4545-48b6-b854-03e1401f09ea | Product name | 1 | 20230112 |
| aead65a2-216e-4ff8-a178-44aab77c24ed | Product name | 1 | 20180531 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 61543-6174-5 | 2024-01-30 | C162847 | 48780-1 | ba0f9c33-108d-a910-e053-dadaa90a0b85 | Scar Zone Burn Gel Topical Analgesic & Antiseptic |
| 61543-6174-5 | 2022-12-16 | C162847 | 48780-1 | ba0f9c33-108d-a910-e053-dadaa90a0b85 | Scar Zone Burn Gel Topical Analgesic & Antiseptic |
| 61543-6174-5 | 2021-01-29 | C162847 | 48780-1 | ba0f9c33-108d-a910-e053-dadaa90a0b85 | Scar Zone Burn Gel Topical Analgesic & Antiseptic |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 61543-6174-5 | Scar Zone Burn Topical Analgesic and Antiseptic | 14 g in 1 TUBE | GEL | 14 | 7 | |
| 61543-6174-5 | Scar Zone Burn Topical Analgesic and Antiseptic | 1 in 1 BOX | GEL | 1 | 7 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 61543-6174 | SCAR ZONE BURN TOPICAL ANALGESIC AND ANTISEPTIC (LIDOCAINE, BENZALKONIUM CHLORIDE) GEL [CCA INDUSTRIES, INC.] | 7 | Legacy NDC, 2 package rows | 20221217_fc53b5c0-df17-4ec1-8804-8fd01ec6a6cb.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| BENZALKONIUM CHLORIDE | ACTIVE INGREDIENT | F5UM2KM3W7 | 4 | |
| LIDOCAINE | ACTIVE INGREDIENT | 98PI200987 | 4 | |
| BENZALKONIUM | ACTIVE MOIETY | 7N6JUD5X6Y | 4 | |
| LIDOCAINE | ACTIVE MOIETY | 98PI200987 | 4 | |
| ALLANTOIN | INACTIVE INGREDIENT | 344S277G0Z | 4 | |
| ALOE VERA LEAF | INACTIVE INGREDIENT | ZY81Z83H0X | 4 | |
| BENZYL ALCOHOL | INACTIVE INGREDIENT | LKG8494WBH | 4 | |
| BUTYLENE GLYCOL | INACTIVE INGREDIENT | 3XUS85K0RA | 4 | |
| CENTELLA ASIATICA | INACTIVE INGREDIENT | 7M867G6T1U | 4 | |
| CITRIC ACID MONOHYDRATE | INACTIVE INGREDIENT | 2968PHW8QP | 4 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 4 | |
| GREEN TEA LEAF | INACTIVE INGREDIENT | W2ZU1RY8B0 | 4 | |
| METHYLISOTHIAZOLINONE | INACTIVE INGREDIENT | 229D0E1QFA | 4 | |
| ONION | INACTIVE INGREDIENT | 492225Q21H | 4 | |
| PHENOXYETHANOL | INACTIVE INGREDIENT | HIE492ZZ3T | 4 | |
| PHYTONADIONE | INACTIVE INGREDIENT | A034SE7857 | 4 | |
| POLYSORBATE 60 | INACTIVE INGREDIENT | CAL22UVI4M | 4 | |
| PROPYLENE GLYCOL | INACTIVE INGREDIENT | 6DC9Q167V3 | 4 | |
| TEA TREE OIL | INACTIVE INGREDIENT | VIF565UC2G | 4 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 4 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 61543-6174 | 61543-6174-5 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| ALLANTOIN | 344S277G0Z | IACT |
| ONION | 492225Q21H | IACT |
| ALOE VERA LEAF | ZY81Z83H0X | IACT |
| BENZYL ALCOHOL | LKG8494WBH | IACT |
| BUTYLENE GLYCOL | 3XUS85K0RA | IACT |
| GREEN TEA LEAF | W2ZU1RY8B0 | IACT |
| CENTELLA ASIATICA | 7M867G6T1U | IACT |
| CITRIC ACID MONOHYDRATE | 2968PHW8QP | IACT |
| GLYCERIN | PDC6A3C0OX | IACT |
| TEA TREE OIL | VIF565UC2G | IACT |
| METHYLISOTHIAZOLINONE | 229D0E1QFA | IACT |
| PHENOXYETHANOL | HIE492ZZ3T | IACT |
| PHYTONADIONE | A034SE7857 | IACT |
| POLYSORBATE 60 | CAL22UVI4M | IACT |
| PROPYLENE GLYCOL | 6DC9Q167V3 | IACT |
| WATER | 059QF0KO0R | IACT |
| LIDOCAINE | 98PI200987 | ACTIB |
| BENZALKONIUM CHLORIDE | F5UM2KM3W7 | ACTIB |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET, CHEWABLE / ORAL | 12 mg | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | INJECTION, SUSPENSION / INTRALESIONAL | 20 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CONCENTRATE / ORAL | 7000 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / TOPICAL | 2.5 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | AEROSOL, FOAM / RECTAL | 1214 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | CREAM / VAGINAL | 0.49 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET / PERIODONTAL | 0.53 mg | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | SPRAY / NASAL | 5 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CAPSULE, EXTENDED RELEASE / ORAL | 8 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION/ DROPS / TOPICAL | 0.75 %w/v | ||
| POLYSORBATE 60 | POLYSORBATE 60 | CAL22UVI4M | AEROSOL, FOAM / TOPICAL | 30 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INFILTRATION | 0.02 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SPONGE / TOPICAL | 40 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CREAM / VAGINAL | 60 mg | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | CAPSULE / ORAL | 450 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | DROPS / ORAL | 300 mg/1ml | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | TABLET, DELAYED RELEASE / ORAL | 36 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET / ORAL | 914 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / RESPIRATORY (INHALATION) | 5 %w/w | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | INJECTION, SOLUTION / INTRAMUSCULAR | 500 mg | ||
| POLYSORBATE 60 | POLYSORBATE 60 | CAL22UVI4M | CREAM / VAGINAL | 200 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRABURSAL | ADJ PH | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUPPOSITORY / RECTAL | 440 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CONCENTRATE / ORAL | 1800 mg | ||
| PHENOXYETHANOL | PHENOXYETHANOL | HIE492ZZ3T | AEROSOL / TOPICAL | 1.05 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SWAB / TOPICAL | 0.05 %w/w | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | CREAM / TOPICAL | 160 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, SUSPENSION / SUBCUTANEOUS | 1.6 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION/ DROPS / OPHTHALMIC | 0.75 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / EPIDURAL | 0.02 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL, METERED / TOPICAL | 1225 mg | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | SOLUTION / INTRAMUSCULAR | 54 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION, CONCENTRATE / INTRAOCULAR | 1 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / INTRAMUSCULAR | 15 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION / RESPIRATORY (INHALATION) | 25 %w/w | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | CREAM / VAGINAL | 1 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SPRAY, METERED / NASAL | 240 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / ORAL | 32400 mg | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | TABLET, DELAYED RELEASE / ORAL | 2.31 mg | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | INJECTION, SOLUTION / SUBCUTANEOUS | 0.95 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | DROPS / ORAL | 200 mg/1ml | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | EMULSION / OPHTHALMIC | 1.5 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | LIQUID / ORAL | 29008 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | ELIXIR / ORAL | 100 mg/5ml | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | PASTE / ORAL | 3822 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | LOTION / TOPICAL | 3392 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | AEROSOL / TOPICAL | 3 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | JELLY / TOPICAL | NA | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / ORAL | 2400 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION/ DROPS / OPHTHALMIC | 12 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION / ORAL | 26208 mg | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | INJECTION, EMULSION / SUBCUTANEOUS | 225 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR | 38 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / INTRAVENOUS | 33750 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION, EXTENDED RELEASE / ORAL | 2000 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | AEROSOL, FOAM / TOPICAL | 21 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | FILM / BUCCAL | 1.48 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION, CONCENTRATE / INTRAVENOUS | 50.33 %w/v | ||
| BENZYL ALCOHOL | BENZYL ALCOHOL | LKG8494WBH | GEL / TOPICAL | 185 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | EMULSION / INTRAVENOUS | 2.2 %w/v |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| eff1461a-d8e5-12f7-e053-2995a90a7cc2 | fc53b5c0-df17-4ec1-8804-8fd01ec6a6cb | 2022-12-16 | Warnings | eff1461a-d8e5-12f7-e053-2995a90a7cc2 fc53b5c0-df17-4ec1-8804-8fd01ec6a6cb |
Adverse event summaries are temporarily unavailable. Other product information remains available.